CHF265.50
2.04%
SIX Swiss Exchange, May 30, 05:31 pm CET
ISIN
CH0012032048
Symbol
ROG
Index
Sector
Industry

Roche Stock price

CHF265.50
-3.80 1.41% 1M
+9.30 3.63% 6M
+10.00 3.91% YTD
+37.20 16.29% 1Y
-65.20 19.72% 3Y
-67.20 20.20% 5Y
-14.20 5.08% 10Y
SIX Swiss Exchange, Closing price Fri, May 30 2025
+5.30 2.04%
ISIN
CH0012032048
Symbol
ROG
Index
Sector
Industry

Key metrics

Market capitalization CHF210.06b
Enterprise Value CHF227.39b
P/E (TTM) P/E ratio 25.73
EV/FCF (TTM) EV/FCF 15.07
EV/Sales (TTM) EV/Sales 3.76
P/S ratio (TTM) P/S ratio 3.47
P/B ratio (TTM) P/B ratio 6.65
Dividend yield 3.65%
Last dividend (FY24) CHF9.70
Revenue growth (TTM) Revenue growth 3.03%
Revenue (TTM) Revenue CHF60.50b
EBIT (operating result TTM) EBIT CHF20.09b
Free Cash Flow (TTM) Free Cash Flow CHF15.09b
Cash position CHF17.32b
EPS (TTM) EPS CHF10.32
P/E forward 14.60
P/S forward 3.31
EV/Sales forward 3.58
Show more

Create a Free Account to create an Roche alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Roche Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a Roche forecast:

10x Buy
40%
11x Hold
44%
4x Sell
16%

Analyst Opinions

25 Analysts have issued a Roche forecast:

Buy
40%
Hold
44%
Sell
16%

Financial data from Roche

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
60,495 60,495
3% 3%
100%
- Direct Costs 15,783 15,783
1% 1%
26%
44,712 44,712
4% 4%
74%
- Selling and Administrative Expenses 13,758 13,758
2% 2%
23%
- Research and Development Expense 13,042 13,042
1% 1%
22%
20,438 20,438
8% 8%
34%
- Depreciation and Amortization 351 351
4% 4%
1%
EBIT (Operating Income) EBIT 20,087 20,087
8% 8%
33%
Net Profit 8,277 8,277
28% 28%
14%

In millions CHF.

Don't miss a Thing! We will send you all news about Roche directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Roche Stock News

AD HOC NEWS
about 23 hours ago
Der schweizerische Pharmakonzern Roche CH0012032048 stellt auf dem diesjährigen Krebskongress ASCO in Chicago weitere Daten zu seinem Krebs-Kandidaten Itovebi vor.
Neutral
GlobeNewsWire
one day ago
Basel, 31 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive final results from the overall survival (OS) analysis of the phase III INAVO120 study. These data showed ItovebiTM (inavolisib), in combination with palbociclib (Ibrance®) and fulvestrant, reduced the risk of death by more than 30% compared with palbociclib and fulvestrant alone. This represents a statistically sig...
Neutral
Business Wire
one day ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive final results from the overall survival (OS) analysis of the Phase III INAVO120 study. These data showed ItovebiTM (inavolisib), in combination with palbociclib (Ibrance®) and fulvestrant, reduced the risk of death by more than 30% compared with palbociclib...
More Roche News

Company Profile

Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Head office Switzerland
CEO Thomas Schinecker
Employees 103,249
Founded 1896
Website www.roche.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today